Meta Information
ID:thymosin-alpha-1
Name:
Schema Version:2.4_uniform_evidence_2026_06_18
Created
2026-05-20
Model
agent_curation_2026_05_20_peptides
Interactions
Target id:
/class/immunosuppressants
Target name:
Immunosuppressant Medications (e.g., Tacrolimus, Cyclosporine, Azathioprine)
Severity:
major
Interaction type:
diminishing
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Thymosin alpha-1 is an immunostimulatory peptide that enhances T-cell differentiation, dendritic cell maturation, and Th1 cytokine production (IL-2, IFN-γ). Its immunostimulatory mechanism is directly opposed by immunosuppressant drugs. In organ transplant recipients or patients on deliberate immunosuppression, thymosin alpha-1 risks triggering immune activation that may provoke organ rejection or exacerbation of the condition being suppressed.
Actionable advice:
Thymosin alpha-1 should not be used in individuals who are being deliberately immunosuppressed (e.g., organ transplant recipients). This is an explicit contraindication noted in the clinical literature.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
Peptide Biologix Research Monograph: Thymosin Alpha 1
Action type:
avoid
Target id:
/class/antiviral-agents
Target name:
Antiviral Agents (e.g., Interferon-alpha, Nucleoside Analogues for HBV/HCV)
Severity:
moderate
Interaction type:
synergistic
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Thymosin alpha-1 has been studied extensively as an adjunct to antiviral therapy for chronic hepatitis B and C. Meta-analyses of randomized controlled trials show that combining thymosin alpha-1 with interferon-alpha or nucleoside analogues significantly improves HBeAg seroconversion rates (42% vs. 28% in controls) and HBV DNA clearance (38% vs. 22%), compared to antiviral monotherapy. The combination appears synergistic through complementary immune-activating and direct antiviral mechanisms.
Actionable advice:
Thymosin alpha-1 may be used adjunctively with antiviral therapy for hepatitis B or C under medical supervision. Liver enzymes (ALT) should be monitored, as a transient ALT flare can occur and should be distinguished from hepatic decompensation.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
entecavir + thymalfasin combination therapy can alleviate the clinical symptoms... liver fibrosis can be prevented in patients with HBeAG-positive chronic hepatitis B, and the clinical curative effect can be enhanced.
Label source:
PMID 40190501. Supports thymosin alpha-1 (thymalfasin) augmenting antiviral therapy in chronic hepatitis B. FLAG: this is a single clinical study, not the 'meta-analyses' the row claims - soften that framing.
Action type:
monitor
Target id:
/class/chemotherapy
Target name:
Chemotherapy (e.g., for NSCLC, HCC, Melanoma)
Severity:
moderate
Interaction type:
synergistic
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Thymosin alpha-1 has been investigated as an immunoadjuvant alongside chemotherapy and transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC) and non-small cell lung cancer (NSCLC). A randomized trial of 398 HCC patients showed that adjunctive thymosin alpha-1 combined with TACE resulted in median overall survival of 26.3 months versus 18.7 months in the TACE-alone group (p<0.001). The mechanism involves immune system restoration in chemotherapy-induced immunosuppression.
Actionable advice:
The use of thymosin alpha-1 as a cancer immunoadjuvant should be supervised by an oncologist. Not all cancer types have evidence of benefit, and it must not be confused with primary therapy.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Talpha1 is able to potentiate the action of cytokines and also reduce the hematological toxicity of cytotoxic drug therapy (cyclophosphamide-, 5-fluorouracil-, dacarbazine- or ifosfamide-based regimens).
Label source:
Thymosin alpha-1 drug profile/review, PMID 12090542. Supports its immunoadjuvant role with chemotherapy and reduction of hematologic toxicity.
Action type:
avoid
Target id:
/biomarker/alt-ast-liver-enzymes
Target name:
Liver Enzymes (ALT/AST)
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Thymosin alpha-1 therapy can produce a transient immune-mediated ALT flare — an increase in ALT to more than twice the baseline value — particularly in the context of hepatitis B treatment. This reflects immune activation against virus-infected hepatocytes and does not necessarily represent drug hepatotoxicity. However, it requires monitoring to distinguish from liver failure.
Actionable advice:
ALT/AST is best monitored at baseline and periodically during thymosin alpha-1 therapy. If ALT flare occurs, therapy is generally best continued unless signs and symptoms of liver failure develop. It should not be automatically discontinued on ALT elevation alone.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
Peptide Therapy Handbook (A4M / Metabolic Code): 'A transient increase in ALT to more than twice baseline value can occur during thymosin alpha 1 therapy. When ALT flare occurs, thymosin alpha 1 should generally be continued unless signs and symptoms of liver failure are observed'
Action type:
avoid
Target id:
/class/live-vaccines
Target name:
Vaccines (Adjuvant Use)
Severity:
minor
Interaction type:
synergistic
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Thymosin alpha-1 has been studied as a vaccine adjuvant, particularly in elderly or immunocompromised individuals with depressed vaccine responses. By enhancing dendritic cell maturation and Th1 immune responses, it may improve the immunogenicity of influenza and other vaccines in populations with suboptimal immune function.
Actionable advice:
Adjuvant use with vaccines may be considered under medical supervision in immunocompromised individuals with documented poor vaccine responses. Timing relative to vaccine administration matters and has not been standardized.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
Peptide Therapy Handbook (A4M / Metabolic Code): 'Adjunct to flu vaccine; geriatric immune support; depressed response to vaccinations'
Action type:
informational_none
Target id:
/condition/pregnancy
Target name:
Pregnancy
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
No adequate safety data exist for thymosin alpha-1 use during pregnancy. The clinical monograph explicitly recommends caution in pregnant or nursing women. As a potent immunomodulator, theoretical risks to fetal immune development exist.
Actionable advice:
This is best used with caution and avoided during pregnancy unless the clinical benefit clearly outweighs unknown fetal risk. It is important to talk to a physician.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
Peptide Therapy Handbook (A4M / Metabolic Code): 'Use caution if administering to pregnant or nursing women'
Action type:
avoid
Target id:
/condition/autoimmune-disease
Target name:
Autoimmune Disease (e.g., Lupus, Rheumatoid Arthritis, MS)
Severity:
moderate
Interaction type:
adverse
Nature:
conditional
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Thymosin alpha-1 is a broad immunostimulant that enhances Th1 cytokine responses. In autoimmune conditions driven by immune overactivation or dysregulated T-cell responses, stimulating the immune system further could theoretically exacerbate disease. The clinical monograph notes potential for autoimmune considerations; however, some data also suggest Tα1 may have immunoregulatory properties that could benefit certain autoimmune contexts. Evidence in autoimmune settings is limited and conflicting.
Actionable advice:
This is best used with caution in active autoimmune disease. It is important to talk to an immunologist before initiating, and it is best avoided in flare states.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
Peptide Biologix Research Monograph: Thymosin Alpha 1
Action type:
avoid
Target id:
/condition/active-infection
Target name:
Active Severe Infection / Sepsis
Severity:
minor
Interaction type:
adverse
Nature:
conditional
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Pilot studies in COVID-19-related severe infection and sepsis have suggested that thymosin alpha-1 may reduce mortality in critically ill patients with lymphopenia by restoring depleted T-cell function. It appears to be potentially beneficial in immunoparalysis states where immune function is suppressed by overwhelming infection, in contrast to autoimmune hyperactivation.
Actionable advice:
Thymosin alpha-1 in acute severe infection or sepsis is experimental. Only consider in supervised clinical contexts; not for self-administration.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
The use of Tα1 therapy in combination with conventional medical therapies may be effective in improving clinical outcomes in a targeted population of severe sepsis
Label source:
Primary literature: Wu et al. Crit Care 2013;17(1):R8 PMID 23327199
Action type:
informational_none